'l, NANOLOGICA

• Nanoporous amorphous silica

• GRAS approved excipient

• Tuneable particle and pore size

• High loading up to 50%50%

• Free-flowing powder

• Licensing agreements/ technology transfer

• Feasibility studies

• Fee for service contracts

• Development of own assets

NLAB Silica™ Business model

• ENHANCING DISSOLUTION KINETICS OFPOORLY SOLUBLE COMPOUNDS

• CONTROLLING RELEASE KINETICS

• IMPROVING BIOAVAILABILITY

• STABILIZING AMORPHOUS FORM

• IMPROVING HANDLING OF APIs

• APPLICABLE FOR A BROAD RANGE OF APIs

PoC Clinical studies Products

Ms. Kia Bengtsson I Director Clinical Development kia.bengtsson@nanologica.com

ContactProfessor Adam Feiler I Chief Technical Officer adam.feiler@nanologica.com

Reformulation of the HIV drug Atazanavir (ATV) using NLAB Silica™ for improved bioavailability in vivo.

For more information, please visit www.nanologica.com

BETTER AND CHEAPER MEDICINE THROUGH NANOPOROUS SILICANanologica develops nanoporous silica for drug delivery formulation. Nanologica's proprietary NLAB Silica™ particles solves problems in pharmaceutical formulations by improving solubility, enhancing bioavailability and protecting APIs from degradation.

Benefits of NLAB Silica™